Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Age greater than or equal to 18 years old and less than or equal to 65 years~ 2. Loa loa microfilaremia \>500 MF/mL and \<2500 MF/mL at screening visit.~ 3. Subject has the capacity to understand the potential risks and benefits and consents to protocol indicated blood draws and follow up visits.~EXCLUSION CRITERIA:~1. Women under 45 years of age, or over 45 years of age with a menstrual period in the preceding 12 months.~2. Currently breastfeeding~3. Currently taking daily medications~4. Known chronic medical conditions, including but not limited to diabetes, renal failure, liver disease, seizure disorder, HIV, malignancy, psychiatric disorder, or any conditions which within the investigators judgement are deemed to be clinically significant.~5. W. bancrofti serologic positivity against Wb123~6. O. volvulus serologic positivity against Ov16~7. HIV by history or clinical signs of HIV/AIDS (e.g. oral thrush, oral/skin lesions of Kaposi s sarcoma, etc.)~8. Any of the following lab abnormalities: Creatinine \>1.5, Platelets \<100,000/mL, Hemoglobin \<12g/dL, alanine aminotransferase or aspartate aminotransferase \>60 U/L, total bilirubin \>1.7mg/dL, absolute neutrophil count equal to or less than 1500/mm(3).~9. Any condition that, in the opinion of the PI, may substantially increase the risk of participation, including any contraindication to imatinib.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Subjects given vitamin placebo
- Imatinib 200mg (Type: EXPERIMENTAL): Subjects given a single dose of imatinib 200mg PO
- Imatinib 400mg (Type: EXPERIMENTAL): Subjects given a single dose of imatinib 400mg PO
- Imatinib 600mg (Type: EXPERIMENTAL): Subjects given a single dose of imatinib 600mg PO

Based on this trial design, predict the completion outcome and termination type (if applicable).